Crinetics Pharmaceuticals Inc - Asset Resilience Ratio
Crinetics Pharmaceuticals Inc (CRNX) has an Asset Resilience Ratio of 87.02% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CRNX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Crinetics Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CRNX current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Crinetics Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CRNX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.15 Billion | 87.02% |
| Total Liquid Assets | $1.15 Billion | 87.02% |
Asset Resilience Insights
- Very High Liquidity: Crinetics Pharmaceuticals Inc maintains exceptional liquid asset reserves at 87.02% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Crinetics Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Crinetics Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Crinetics Pharmaceuticals Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Crinetics Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 81.58% | $926.35 Million | $1.14 Billion | +5.63pp |
| 2024-12-31 | 75.95% | $1.09 Billion | $1.43 Billion | -3.33pp |
| 2023-12-31 | 79.27% | $503.66 Million | $635.35 Million | -6.41pp |
| 2022-12-31 | 85.68% | $301.75 Million | $352.18 Million | +47.79pp |
| 2021-12-31 | 37.89% | $133.01 Million | $351.01 Million | -4.51pp |
| 2020-12-31 | 42.41% | $77.79 Million | $183.44 Million | -17.47pp |
| 2019-12-31 | 59.88% | $78.07 Million | $130.38 Million | -9.49pp |
| 2018-12-31 | 69.36% | $118.90 Million | $171.41 Million | -- |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more